Spinal cord stimulation through the skin to help arm movement after spinal cord injury
Tests skin-applied spinal stimulation versus sham during rehabilitation in adults with recent spinal cord injury.
Key facts
- Who runs it
- University College, London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Upper Limb Spinal Cord Stimulation for Rehabilitation Enhancement
- Status
- Recruiting
- People taking part
- 18 people, planned
- Started
- 28 Jun 2023
- Expected to end
- 16 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transcutaneous spinal cord stimulation added to inpatient rehabilitation
- Sham transcutaneous spinal cord stimulation (placebo) added to inpatient rehabilitation
- Record updated
- 10 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent spinal cord injury in the neck (C1-C8) who are inpatients at the RNOH. It tests skin-surface spinal cord stimulation added to rehabilitation to help arm and hand function.
- Age
- Over the age of 18
- Sex
- All sexes can join.
- Disease stage
- Recent spinal cord injury at level C1-C8, AIS grade A-D, while an inpatient at the RNOH.
Main reasons for not taking part
- Women who are pregnant, planning pregnancy or breastfeeding
- A heart pacemaker or another active device where the electrodes go
- Spinal cancer, or spinal cord injury caused by a cancerous growth
- Other conditions affecting the arms, such as nerve damage, complex regional pain syndrome or other muscle and bone diagnoses
- Autoimmune disorder, ongoing infection, uncontrolled autonomic dysreflexia (sudden dangerous blood pressure rises) or degenerative nerve diseases
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Over the age of 18
- Recent spinal cord injury (inpatient at the RNOH)
- Spinal cord injury level C1-C8
- AIS A-D
- Willing and able to provide informed consent
Who cannot take part
- Those who have a cardiac pacemaker
- Spinal malignancy
- Auto-immune disorder
- Ongoing infection
- Complex regional pain syndrome
- Neurological degenerative diseases
- Women who are pregnant, planning pregnancy or breastfeeding
- Active device at stimulating electrode site
- Any other musculoskeletal diagnosis affecting the upper limbs
- Spinal cord injury due to cancerous growth
- Uncontrolled autonomic dysreflexia
- Peripheral nerve damage affecting the upper limbs
- Taking part in a conflicting research study
- People who are unable to tolerate TSCS during their first session
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In the United Kingdom, there are more than 1000 new cases of spinal cord injury (SCI) each year, with around half of these injuries affecting the cervical spine. People who have reduced function and control affecting their upper limbs may have difficulty carrying out activities of daily living (ADLs), significantly affecting their independence. Recovering even partial upper limb function is a top priority among tetraplegics.
Read full original descriptionShow less
Regaining voluntary function in the upper limb can have a huge impact on quality of life. Using TSCS in the upper limb for acute SCI can benefit patients early in their rehabilitation, and may reduce the number of patients with problematic spasticity at discharge. Transcutaneous spinal cord stimulation (TSCS) may provide a low-cost method of improving function and spasticity in this cohort.
The aim of this feasibility study is to assess and compare the impact of adding TSCS to the standard rehabilitation of inpatients with acute SCI, compared to a sham (placebo) TSCS intervention added to standard rehabilitation, in an effort to enhance upper limb control and function.
The 2 groups in the trial
- Sham transcutaneous spinal cord stimulation (placebo) added to inpatient rehabilitationExisting treatment, for comparison
Standard inpatient rehabilitation received at the Royal National Orthopaedic Hospital NHS Trust
- Transcutaneous spinal cord stimulation added to inpatient rehabilitationTreatment being tested
Transcutaneous spinal cord stimulation added to standard inpatient rehabilitation, targetting the upper limbs, received at the Royal National Orthopaedic Hospital NHS Trust
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Upper Limb Spinal Cord Stimulation for Rehabilitation Enhancement
- Plain-language title
- Spinal cord stimulation through the skin to help arm movement after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 December 2025